How BeiGene Built a Billion-Dollar Biotech in China: Case Study

The story of BeiGene’s rise from a Beijing startup to a global oncology powerhouse — a blueprint for biotechnology success in China

Introduction: China’s First Global Biotech Champion

BeiGene Ltd. (百济神州) represents a watershed moment for China’s biotechnology industry. Founded in 2010 by the Chinese-American scientist Dr. Wang Xiaodong and the American entrepreneur John Oyler, BeiGene has become the first Chinese biotech company to achieve meaningful global commercial success, with approved medicines in over 60 countries and annual revenues exceeding USD 3 billion. Its journey from a small research operation in Beijing’s Zhongguancun technology hub to a publicly traded company on three major stock exchanges—NASDAQ (2016), Hong Kong Stock Exchange (2018), and Shanghai Stock Exchange STAR Market (2021)—offers a masterclass in building a globally competitive biotech company from a China base.

BeiGene’s trajectory is particularly significant for foreign companies evaluating China’s biotech ecosystem. The company has demonstrated that it is possible to discover, develop, manufacture, and commercialise innovative medicines from China for global markets, challenging the traditional paradigm that biotech innovation is the exclusive domain of the United States and Europe.

This case study examines BeiGene’s founding story, its strategic decisions, its flagship product tislelizumab, its financing journey, the challenges it has overcome, and the lessons it offers for foreign companies and investors in China’s biotech sector.

1. Founding and Vision: A Hybrid Model

1.1 The Founders

BeiGene’s founding team combined complementary strengths that proved critical to the company’s success:

• Dr. Wang Xiaodong (王晓东): A world-renowned cell biologist who discovered key proteins in the programmed cell death pathway. Dr. Wang was the first Chinese-born scientist to be elected to the US National Academy of Sciences (2004) and later founded the National Institute of Biological Sciences (NIBS) in Beijing. His scientific reputation and connections within China’s research community provided the company with academic credibility and talent access.
• John Oyler: An American entrepreneur with extensive experience in the pharmaceutical and biotech industry, including co-founding BioDuro (a CRO that was later acquired by PPD). Oyler brought business development expertise, Western biotech industry connections, and a sophisticated understanding of global pharmaceutical markets and regulatory pathways.

This combination—deep Chinese scientific leadership with Western commercial and business expertise—created a hybrid model that became a defining characteristic of BeiGene’s approach.

1.2 The Founding Thesis

BeiGene was founded on the conviction that China’s growing scientific talent pool, combined with its cost advantages, could produce innovative drug candidates that would be competitive on the global stage. The founding thesis included several key elements:

• China-based discovery research leveraging top-tier Chinese scientists at significantly lower cost than US-based equivalents
• Global clinical development from the outset, designing clinical trials that would meet FDA, EMA, and NMPA requirements simultaneously
• Focus on oncology immunology targeting well-validated mechanisms with the potential for best-in-class or first-in-class positioning
• Internal manufacturing capability to ensure supply chain security and cost control
• Direct commercialisation rather than licensing to established pharmaceutical partners, retaining greater value capture

2. Tislelizumab: The Flagship Product

2.1 Development Journey

Tislelizumab (Brukinsa for the BTK inhibitor; tislelizumab is the PD-1 inhibitor marketed as Tevimbra in some markets) is BeiGene’s most advanced and commercially important product. The company’s PD-1 inhibitor was designed with a unique Fc region modification intended to reduce binding to Fc-gamma receptors on macrophages, thereby potentially enhancing anti-tumour activity by reducing antibody-dependent cellular phagocytosis (ADCP) that could deplete activated T-cells.

The clinical development programme for tislelizumab was one of the most ambitious ever conducted by a Chinese biotech company:

• Over 20 clinical trials across 30+ countries involving more than 10,000 patients
• Multiple indications including non-small cell lung cancer (NSCLC), oesophageal squamous cell carcinoma (ESCC), gastric cancer, hepatocellular carcinoma (HCC), and nasopharyngeal carcinoma
• Head-to-head trials against established PD-1 inhibitors (pembrolizumab, nivolumab) in certain indications
• Regulatory submissions to the US FDA, European Medicines Agency (EMA), China NMPA, and multiple other national regulatory authorities

2.2 Regulatory Milestones

Tislelizumab achieved several landmark regulatory approvals:

• 2019 (China): First approval by China’s NMPA for classical Hodgkin lymphoma after failure of prior therapy
• 2020–2023 (China): Multiple additional approvals for ESCC, NSCLC, HCC, and gastric cancer in China
• 2023 (Europe): EMA approval for ESCC, marking one of the first Chinese-developed PD-1 inhibitors to gain European approval
• 2024 (USA): FDA approval for ESCC following a resubmission that addressed earlier Complete Response Letter (CRL) concerns about manufacturing and clinical data
• 2025–2026: Continued global regulatory expansion across 40+ countries and 10+ indications

3. The Financing Story: Raising Capital for Global Ambition

BeiGene’s financing journey is as remarkable as its scientific achievements. The company raised over USD 10 billion across multiple rounds, making it one of the best-capitalised biotech companies globally:

3.1 Venture Capital Phase (2010–2016)

Initial funding came from prominent investors including:

• New Enterprise Associates (NEA)
• China Merchant Group and CCB International
• Sequoia Capital China
• Gao Capital and other healthcare-focused funds

3.2 Public Listings (2016–2021)

BeiGene executed a triple-listing strategy that provided access to deep capital pools:

• NASDAQ (2016): IPO raising approximately USD 158 million (followed by multiple follow-on offerings)
• HKEX (2018): Secondary listing raising approximately USD 900 million in one of the first biotech IPOs under Hong Kong’s new Chapter 18A biotech listing rules
• STAR Market (2021): Shanghai listing raising approximately USD 3 billion, one of the largest biotech IPOs in China’s history

The triple-listing strategy was innovative and strategically important. It allowed BeiGene to access capital from both Western and Chinese investors, hedge against market-specific volatility, and build brand recognition in all three markets.

3.3 Strategic Collaboration Revenue

In addition to equity financing, BeiGene secured significant non-dilutive funding through strategic collaborations:

• Amgen collaboration (2019): A USD 2.7 billion partnership to commercialise Amgen’s cancer drugs in China, providing BeiGene with immediate revenue and commercial infrastructure
• Novartis collaboration (2021): A USD 2.2 billion deal granting Novartis rights to develop and commercialise tislelizumab in the US, Europe, and Japan (later terminated in 2023, with rights returning to BeiGene)
• Other collaborations: Strategic partnerships with Mirati Therapeutics, Leap Therapeutics, and others for combination therapy studies

4. Commercial Strategy: Building a China-First, Global-Capable Engine

4.1 China Commercial Infrastructure

BeiGene built one of the largest oncology sales forces in China, with over 2,000 commercial employees covering major hospitals and oncology centres across the country. This infrastructure enables the company to:

• Reach over 10,000 hospitals in China
• Provide comprehensive oncology product portfolios to healthcare providers
• Navigate China’s complex hospital tendering, reimbursement, and National Reimbursement Drug List (NRDL) processes
• Build relationships with key opinion leaders (KOLs) across China’s oncology community

4.2 Global Commercialisation

Unlike most Chinese biotech companies that license their products to Western partners, BeiGene has invested in building its own global commercial infrastructure:

• US headquarters in Cambridge, Massachusetts, with commercial and medical affairs teams
• European commercial operations in Switzerland, the UK, Germany, and other markets
• Manufacturing facilities in China (Suzhou and Guangzhou) and a planned facility in the US
• Global regulatory affairs team managing submissions across 40+ regulatory jurisdictions

5. Manufacturing: Vertical Integration as a Strategic Asset

BeiGene has invested heavily in internal manufacturing capabilities:

• Suzhou facility: Small molecule API and solid dose manufacturing, supporting the production of the BTK inhibitor Brukinsa (zanubrutinib) and other small molecule programmes
• Guangzhou facility: Biologics manufacturing campus with up to 120,000L bioreactor capacity for monoclonal antibody production, including tislelizumab
• New Jersey facility (planned): A clinical-stage manufacturing facility to support US clinical trials and eventual commercial supply, designed to address FDA regulatory concerns about overseas manufacturing inspection

This vertical integration provides several advantages: supply chain security, cost control, quality assurance, and the ability to respond rapidly to clinical and commercial demand fluctuations. Internal manufacturing also positions BeiGene to potentially offer contract manufacturing services in the future, similar to the CDMO model.

6. Challenges and Setbacks

6.1 Regulatory Hurdles in the US

BeiGene’s path to the US market was not smooth. The company received a Complete Response Letter (CRL) from the FDA in 2022 for its application for tislelizumab in ESCC, citing concerns about:

• The adequacy of clinical data from a China-only pivotal trial to support US approval
• Manufacturing facility inspection issues
• The need for additional data to demonstrate applicability to US patient populations

BeiGene addressed these concerns through additional global clinical data and manufacturing improvements, ultimately receiving FDA approval in 2024. This experience highlighted the importance of designing global clinical trials that meet FDA standards from the outset and preparing facilities for US regulatory inspection.

6.2 Intense Competition

BeiGene operates in one of the most competitive segments of oncology—PD-1 inhibitors. The market includes established products from Merck (Keytruda/pembrolizumab), Bristol-Myers Squibb (Opdivo/nivolumab), Roche (Tecentriq/atezolizumab), and numerous Chinese competitors including Junshi Biosciences (Toripalimab), Innovent Biologics (Sintilimab), and Hengrui Medicine (Camrelizumab). BeiGene has differentiated through:

• Unique Fc engineering designed to improve efficacy (though this remains clinically debated)
• A broad clinical development programme covering multiple indications
• A focus on developing markets where PD-1 access remains limited
• Competitive pricing, particularly in China where PD-1 inhibitor prices have fallen by over 50% through NRDL negotiations

6.3 Geopolitical Risk

As a Chinese-founded company with significant US operations and management, BeiGene occupies a complex position in US-China technology competition. While the BIOSECURE Act proposals primarily target Chinese CROs and CDMOs rather than innovative biotech companies, BeiGene’s China-based R&D and manufacturing could face increasing scrutiny. The company has responded by:

• Building US-based manufacturing and R&D capabilities
• Emphasising its global governance structure (CEO John Oyler is American, the company’s board includes prominent US and European members)
• Diversifying its clinical trial sites across multiple geographies
• Maintaining transparent communications with regulators

7. Key Metrics: From Startup to Billion-Dollar Biotech

• Employees: Over 10,000 globally (2025)
• Revenue: Exceeded USD 3 billion in 2025, driven primarily by Brukinsa and tislelizumab sales
• Products: Two internally discovered approved medicines (Brukinsa, tislelizumab) plus partnered products
• Clinical pipeline: Over 20 clinical-stage assets, including programmes in bispecific antibodies, cell therapies, and targeted protein degradation
• Market capitalisation: Has exceeded USD 30 billion at peak, though volatile with market conditions
• Global reach: Approved in 60+ countries across six continents
• Manufacturing capacity: Over 200,000L total bioreactor capacity across China facilities

8. Lessons for Foreign Companies in China’s Biotech Ecosystem

1. The hybrid leadership model works: BeiGene’s combination of Chinese scientific leadership and Western commercial/regulatory expertise proved powerful. Foreign companies should consider partnership structures that combine local scientific talent with global business expertise.
2. Think global from day one: BeiGene designed its clinical trials and regulatory strategy for global markets from the outset, not as an afterthought. This approach, while more expensive upfront, paid dividends in market access.
3. Capital is available for the right story: BeiGene raised over USD 10 billion by telling a compelling global story. Companies that can articulate a clear path to global commercialisation can access deep capital pools across multiple markets.
4. Manufacturing matters: Vertical integration provided BeiGene with supply chain security and quality control. Companies outsourcing manufacturing should ensure robust quality agreements and supply chain redundancy.
5. China market access requires local expertise: BeiGene’s success in securing NRDL listing and hospital access demonstrates the importance of dedicated local commercial infrastructure and expertise.
6. Regulatory persistence is essential: BeiGene’s FDA journey, including a CRL and resubmission, shows that regulatory setbacks are common and can be overcome with focused effort and additional data.
7. Geopolitical risk must be managed proactively: Companies operating at the intersection of China and global markets must invest in governance structures, geographic diversification, and transparent communications.

Conclusion: BeiGene’s Legacy and the Future of Chinese Biotech

BeiGene’s journey from a small Zhongguancun startup to a globally competitive biotech company is one of the most significant success stories in the history of China’s life sciences industry. The company has demonstrated that China-based drug discovery can produce globally competitive products, that Chinese biotech companies can navigate complex international regulatory pathways, and that a China-founded company can build a US-European-China commercial infrastructure capable of competing with established pharmaceutical giants.

The challenges that BeiGene has faced—regulatory hurdles, competitive pressure, geopolitical risk—are likely to be common experiences for any foreign company or China-founded biotech with global ambitions. However, the company’s success in overcoming these challenges offers a roadmap for others. BeiGene has not only built a valuable business; it has built an ecosystem, a talent pool, and a proof of concept for China’s potential as a source of global pharmaceutical innovation.

For foreign companies evaluating China’s biotech ecosystem, BeiGene’s story is both inspiring and instructive. It shows that the ingredients for biotech success exist in China—world-class science, entrepreneurial drive, access to capital, and a large market. But it also shows that success requires exceptional execution, global thinking, regulatory sophistication, and resilience in the face of inevitable setbacks.